Optimisation of pharmacotherapy in psychiatry through therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests: Focus on antipsychotics.

Autor:	Hart XM; Department of Molecular Neuroimaging, Medical Faculty Mannheim, Central Institute of Mental Health, University of Heidelberg, Mannheim, Germany.; Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan., Gründer G; Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.; German Center for Mental Health (DZPG), Partner Site Mannheim, Heidelberg, Germany., Ansermot N; Department of Psychiatry, Unit of Pharmacogenetics and Clinical Psychopharmacology, Center for Psychiatric Neuroscience, Lausanne University Hospital, Prilly, Switzerland., Conca A; Dipartimento di Psichiatria, Comprensorio Sanitario di Bolzano, Bolzano, Italy., Corruble E; Service Hospitalo-Universitaire de Psychiatrie, Hôpital de Bicêtre, Université Paris-Saclay, AP-HP, Le Kremlin-Bicêtre, France.; Equipe MOODS, Inserm U1018, CESP (Centre de Recherche en Epidémiologie et Sante des Populations), Le Kremlin-Bicêtre, France., Crettol S; Department of Psychiatry, Unit of Pharmacogenetics and Clinical Psychopharmacology, Center for Psychiatric Neuroscience, Lausanne University Hospital, Prilly, Switzerland., Cumming P; Department of Nuclear Medicine, Bern University Hospital, Bern, Switzerland.; School of Psychology and Counseling, Queensland University of Technology, Brisbane, Australia., Frajerman A; Service Hospitalo-Universitaire de Psychiatrie, Hôpital de Bicêtre, Université Paris-Saclay, AP-HP, Le Kremlin-Bicêtre, France.; Equipe MOODS, Inserm U1018, CESP (Centre de Recherche en Epidémiologie et Sante des Populations), Le Kremlin-Bicêtre, France., Hefner G; Forensic Psychiatry, Vitos Clinic for Forensic Psychiatry, Eltville, Germany., Howes O; Department of Psychosis Studies, IoPPN, King's College London, London, UK.; Faculty of Medicine, Institute of Clinical Sciences (ICS), Imperial College London, London, UK., Jukic MM; Department of Physiology, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia.; Pharmacogenetics Section, Department of Physiology and Pharmacology, Karolinska Institutet, Solna, Sweden., Kim E; Department of Psychiatry, Seoul National University College of Medicine, Seoul, Republic of Korea., Kim S; Department of Neuropsychiatry, Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Republic of Korea., Maniscalco I; Dipartimento di Psichiatria, Comprensorio Sanitario di Bolzano, Bolzano, Italy., Moriguchi S; Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan., Müller DJ; Department of Psychiatry, Psychosomatics and Psychotherapy, Center of Mental Health, University Hospital of Würzburg, Würzburg, Germany.; Pharmacogenetics Research Clinic, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.; Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada., Nakajima S; Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan., Osugo M; Department of Psychosis Studies, IoPPN, King's College London, London, UK.; Faculty of Medicine, Institute of Clinical Sciences (ICS), Imperial College London, London, UK., Paulzen M; Department of Psychiatry, Psychotherapy and Psychosomatics, RWTH Aachen University, Aachen, Germany.; JARA - Translational Brain Medicine, Alexianer Center for Mental Health, Aachen, Germany., Ruhe HG; Department of Psychiatry, Radboudumc, Nijmegen, Netherlands.; Donders Institute for Brain, Cognition and Behavior, Radboud University, Nijmegen, Netherlands., Scherf-Clavel M; Department of Psychiatry, Psychosomatics and Psychotherapy, Center of Mental Health, University Hospital of Würzburg, Würzburg, Germany., Schoretsanitis G; Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich, Zurich, Switzerland., Serretti A; Department of Medicine and Surgery, Kore University of Enna, Enna, Italy., Spina E; Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy., Spigset O; Department of Clinical Pharmacology, St. Olav University Hospital, Trondheim, Norway.; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway., Steimer W; Institute of Clinical Chemistry and Pathobiochemistry, Technical University Munich, Munich, Germany., Süzen SH; Department of Pharmaceutic Toxicology, Faculty of Pharmacy, Ankara University, Ankara, Turkey., Uchida H; Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan., Unterecker S; Department of Psychiatry, Psychosomatics and Psychotherapy, Center of Mental Health, University Hospital of Würzburg, Würzburg, Germany., Vandenberghe F; Department of Psychiatry, Unit of Pharmacogenetics and Clinical Psychopharmacology, Center for Psychiatric Neuroscience, Lausanne University Hospital, Prilly, Switzerland., Verstuyft C; Equipe MOODS, Inserm U1018, CESP (Centre de Recherche en Epidémiologie et Sante des Populations), Le Kremlin-Bicêtre, France.; Department of Molecular Genetics, Pharmacogenetics and Hormonology, Bicêtre University Hospital Paris-Saclay, Assistance Publique-Hôpitaux de Paris, Paris, France., Zernig G; Department of Pharmacology, Medical University Innsbruck, Hall in Tirol, Austria.; Private Practice for Psychotherapy and Court-Certified Witness, Hall in Tirol, Austria., Hiemke C; Department of Psychiatry and Psychotherapy and Institute of Clinical Chemistry and Laboratory Medicine, University Medical Center of Mainz, Mainz, Germany., Eap CB; Department of Psychiatry, Unit of Pharmacogenetics and Clinical Psychopharmacology, Center for Psychiatric Neuroscience, Lausanne University Hospital, Prilly, Switzerland.; School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Geneva, Switzerland.; Center for Research and Innovation in Clinical Pharmaceutical Sciences, University of Lausanne, Lausanne, Switzerland.; Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, University of Lausanne, Lausanne, Switzerland.
Jazyk:	angličtina
Zdroj:	The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry [World J Biol Psychiatry] 2024 Nov; Vol. 25 (9), pp. 451-536. Date of Electronic Publication: 2024 Sep 01.
DOI:	10.1080/15622975.2024.2366235
Abstrakt:	Background: For psychotic disorders (i.e. schizophrenia), pharmacotherapy plays a key role in controlling acute and long-term symptoms. To find the optimal individual dose and dosage strategy, specialised tools are used. Three tools have been proven useful to personalise drug treatments: therapeutic drug monitoring (TDM) of drug levels, pharmacogenetic testing (PG), and molecular neuroimaging. Methods: In these Guidelines, we provide an in-depth review of pharmacokinetics, pharmacodynamics, and pharmacogenetics for 45 antipsychotics. Over 30 international experts in psychiatry selected studies that have measured drug concentrations in the blood (TDM), gene polymorphisms of enzymes involved in drug metabolism, or receptor/transporter occupancies in the brain (positron emission tomography (PET)). Results: Study results strongly support the use of TDM and the cytochrome P450 (CYP) genotyping and/or phenotyping to guide drug therapies. Evidence-based target ranges are available for titrating drug doses that are often supported by PET findings. Conclusion: All three tools discussed in these Guidelines are essential for drug treatment. TDM goes well beyond typical indications such as unclear compliance and polypharmacy. Despite its enormous potential to optimise treatment effects, minimise side effects and ultimately reduce the global burden of diseases, personalised drug treatment has not yet become the standard of care in psychiatry.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu